Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer.

@article{Rebattu2001DosefindingPA,
  title={Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer.},
  author={Paul Rebattu and Xavier Quantin and Claude Joseph Ardiet and Jean François Mor{\`e}re and Madeleine Azarian and M P Schuller-Lebeau and Jean-Louis Pujol},
  journal={Lung cancer},
  year={2001},
  volume={33 2-3},
  pages={277-87}
}
BACKGROUND The good efficacy-toxicity ratio of both docetaxel and gemcitabine in non-small cell lung cancer (NSCLC) stimulates the investigation of the combination of these drugs as a first line chemotherapy. This two-step study firstly aimed at determining the maximum tolerated and recommended doses of docetaxel given every 3 weeks in combination with a fixed dose of gemcitabine; the phase I study paid particular attention to pharmacokinetics. Afterwards, the safety and efficacy of the… CONTINUE READING
10 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

Similar Papers

Loading similar papers…